Influence of drugs with hyaluronidase activity on the survival of animals with a purulent-inflammatory process in the abdominal organs

Abstract

BACKGROUND: The optimization of the pharmacokinetics of antibiotics is an important aspect in improving the effectiveness of therapy for intra-abdominal infections. Thus, studying the survival of experimental animals with a simulated purulent-inflammatory process in abdominal organs using the combined use of antibacterial agents with endolymphatic agents is worthwhile.

AIMS: To examine the effect of the co-administration of cefotaxime and hyaluronidase or bovgyaluronidase azoximer on the survival of mice with a purulent-inflammatory process of the abdominal organs.

MATERIALS AND METHODS: The purulent-inflammatory process of the abdominal organs, which was simulated by the intraperitoneal administration of a lethal dose of Staphylococcus aureus microbial suspension to mice, was evaluated. Four study groups were formed, with 28 animals each. Group 1 did not receive treatment, group 2 was administered with cefotaxime, and groups 3 and 4 received antibiotics after preliminary administration of hyaluronidase or bovgialuronidase azoximer. For the statistical analysis of animal survival, the Kaplan–Meier multiple assessment method was used, and a univariate analysis using a log-rank test was employed to identify significant differences between the groups.

RESULTS: During the study, a single injection of cefotaxime alone and in combination with other studied drugs promoted the survival of some mice with a simulated purulent-inflammatory process of the abdominal organs compared with the untreated group, and at the end of the experiment (day 7), 100% of the animals died. Moreover, the best results were achieved with the initial administration of hyaluronidase or bovhyaluronidase azoximer. Thus, on day 7 of observation, >70% of the animals in groups that received both an antibiotic and hyaluronidase or bovgyaluronidase azoximer survived. No statistically significant differences were found in the effect of these drugs on animal survival in the presence of an experimental purulent-inflammatory process.

CONCLUSION: A single injection of cefotaxime alone or in combination with other studied drugs ensures the survival of some mice with a simulated purulent-inflammatory process of the abdominal cavity compared with the control group, in which 100% of the animals died by the end of the experiment (day 7). Moreover, the best results were achieved in groups initially administered with hyaluronidase or bovgialuronidase azoximer.

Keywords

endolymphatic conductors / hyaluronidase / bovgialuronidase azoximer / cefotaxime / intraabdominal infection / survival

References

[1] Sartelli M, Coccolini F, Kluger Y, et al. WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections. World J Emerg Surg. 2021;16(1):49. doi: 10.1186/s13017-021-00387-8

[2] Sartelli M., Coccolini F., Kluger Y., et al. WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections // World J Emerg Surg. 2021. Vol. 16, N 1. P. 49. doi: 10.1186/s13017-021-00387-8

[3] Morvan AC, Hengy B, Garrouste-Orgeas M, et al. Impact of species and antibiotic therapy of enterococcal peritonitis on 30-day mortality in critical care-an analysis of the OUTCOMEREA database. Crit Care. 2019;23(1):307. doi: 10.1186/s13054-019-2581-8

[4] Morvan A.C., Hengy B., Garrouste-Orgeas M., et al. Impact of species and antibiotic therapy of enterococcal peritonitis on 30-day mortality in critical care-an analysis of the OUTCOMEREA database // Crit Care. 2019. Vol. 23, N 1. P. 307. doi: 10.1186/s13054-019-2581-8

[5] Luo X, Li L, Xuan J, et al. Risk factors for enterococcal intra-abdominal infections and outcomes in intensive care unit patients. Surg Infect (Larchmt). 2021;22(8):845–853. doi: 10.1089/sur.2020.417

[6] Luo X., Li L., Xuan J., et al. Risk factors for enterococcal intra-abdominal infections and outcomes in intensive care unit patients // Surg Infect (Larchmt). 2021. Vol. 22, N 8. P. 845–853. doi: 10.1089/sur.2020.417

[7] Bassetti M, Rello J, Blasi F, et al. Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. Int J Antimicrob Agents. 2020;56(6):106184. doi: 10.1016/j.ijantimicag.2020.106184

[8] Bassetti M., Rello J., Blasi F., et al. Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections // Int J Antimicrob Agents. 2020. Vol. 56, N 6. P. 106184. doi: 10.1016/j.ijantimicag.2020.106184

[9] De Waele JJ, Schouten J, Beovic B, et al. Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions — a viewpoint of experts. Intensive Care Med. 2020;46(2):236–244. doi.org/10.1007/s00134-019-05871-z

[10] De Waele J.J., Schouten J., Beovic B., et al. Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions — a viewpoint of experts // Intensive Care Med. 2020. Vol. 46, N 2. P. 236–244. doi: 10.1007/s00134-019-05871-z

[11] Gatti M, Viaggi B, Rossolini GM, et al. An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of BSIs, cUTIs, and cIAIs caused by enterobacterales in critically ill adult patients. Infect Drug Resist. 2021;14:2461–2498. doi: 10.2147/IDR.S314241

[12] Gatti M., Viaggi B., Rossolini G.M., et al. An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of BSIs, cUTIs, and cIAIs caused by enterobacterales in critically ill adult patients // Infect Drug Resist. 2021. Vol. 14. P. 2461–2498. doi: 10.2147/IDR.S314241

[13] Wasserman RL. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy. 2014;6(5):553–567. doi: 10.2217/imt.14.34

[14] Wasserman R.L. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies // Immunotherapy. 2014. Vol. 6, N 5. P. 553–567. doi: 10.2217/imt.14.34

[15] Locke KW, Maneval DC, LaBarre MJ. ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv. 2019;26(1): 98–106. doi: 10.1080/10717544.2018.1551442

[16] Locke K.W., Maneval D.C., LaBarre M.J. ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20 // Drug Deliv. 2019. Vol. 26, N 1. P. 98–106. doi: 10.1080/10717544.2018.1551442

[17] Orehova JeM, Konchugova TV, Luk’janova TV, i dr. Primenenie preparata «Longidaza 3000 ME» pri zabolevanijah, soprovozhdajushhihsja patologiej soedinitel’noj tkani. Moscow; 2008. (In Russ).

[18] Орехова Э.М., Кончугова Т.В., Лукьянова Т.В., и др. Применение препарата «Лонгидаза 3000 МЕ» при заболеваниях, сопровождающихся патологией соединительной ткани. Москва, 2008.

[19] Konenkov VI, Borodin JuI, Ljubarskij MS. Limfologija. Novosibirsk: Izdatel’skij dom «Manuskript»; 2012. (In Russ).

[20] Коненков В.И., Бородин Ю.И., Любарский М.С. Лимфология. Новосибирск : Издательский дом «Манускрипт», 2012.

[21] Levin JuM, Rodionova OM, Gurina LV, i dr. Patogeneticheskaja terapija (ustranenie anahronizmov). Novye principy i metody. Moscow: Izdatel’stvo RUDN; 2014. (In Russ).

[22] Левин Ю.М., Родионова О.М., Гурина Л.В., и др. Патогенетическая терапия (устранение анахронизмов). Новые принципы и методы. Москва : Издательство РУДН, 2014.

[23] Vtorenko VI, Esipov AV, Musailov VA, Shishlo VK. Limfaticheskaja terapija v hirurgicheskoj praktike. SurgicaL Practice. 2014;(3):4–9. (In Russ).

[24] Вторенко В.И., Есипов А.В., Мусаилов В.А., Шишло В.К. Лимфатическая терапия в хирургической практике // Хирургическая практика. 2014. № 3. С. 4–9.

[25] Charyshkin AL, Dementyev IN. Results regionarny limfotropny of therapy of patients sharp paraproktitis. Ul’yanovskii mediko-biologicheskii zhurnal. 2013;(3)45–53. (In Russ).

[26] Чарышкин А.Л., Дементьев И.Н. Результаты регионарной лимфотропной терапии больных острым парапроктитом // Ульяновский медико-биологический журнал. 2013. № 3. С. 45–53.

[27] Usubakunov UE. Effectiveness of lymph-stimulating therapy in syndrome systemic inflammatory reaction in abdominal surgery. Vestnik of KSMA named after I.K. Akhunbayev. 2015;2(2):155–158. (In Russ).

[28] Усубакунов У.Э. Эффективность лимфостимулирующей терапии при синдроме системной воспалительной реакции в абдоминальной хирургии // Вестник КГМА им. И.К. Ахунбаева. 2015. Т. 2, № 2. С. 155–158.

[29] Kraynyukov PE, Safonov OV, Kolodkin BB, Kokorin VV. Pyoinflammatory diseases brush: modern features of complex treatment. Bulletin of Pirogov National Medical & Surgical Center. 2016;11(3):48–54. (In Russ).

[30] Крайнюков П.Е., Сафонов О.В., Колодкин Б.Б., Кокорин В.В. Гнойно-воспалительные заболеваниями кисти: современные особенности комплексного лечения // Вестник Национального медико-хирургического центра им. Н.И. Пирогова. 2016. Т. 11, № 3. С. 48–54.

[31] Oschepkova OV, Putalova IN, Barinov SV, Sabitov SS. The way of treatment of complicated forms of inflammatory diseases of appendages of uterus by application lymphotropic introductions of antibacterial medicine. Omsk Scientific Bulletin. 2012;(1):114–119. (In Russ).

[32] Ощепкова О.В., Путалова И.Н., Баринов С.В., Сабитов Ш.С. Способ лечения осложненных форм воспалительных заболеваний придатков матки путем применения лимфотропного введения антибактериального препарата // Омский научный вестник. 2012. № 1. С. 114–119.

[33] Skripcova SA, Tverdohleb SA. Ocenka rezul’tatov lechenija skleroza shejki mochevogo puzyrja. Saratov Journal of Medical Scientific Research. 2016;12(2):232. (In Russ).

[34] Скрипцова С.А., Твердохлеб С.А. Оценка результатов лечения склероза шейки мочевого пузыря // Саратовский научно-медицинский журнал. 2016. Т. 12, № 2. С. 232.

[35] Sviridkina LP, Batysheva TT, Kuzmina ZV, Toporova SG. Lymphotropic therapy of dorsopathy in case of disc hernia if the lumbar part of the spinal column. Vestnik Rossiiskogo gosudarstvennogo meditsinskogo universiteta. 2011;(1):36–40. (In Russ).

[36] Свиридкина Л.П., Батышева Т.Т., Кузьмина З.В., Топорова С.Г. Лимфотропная терапия дорсопатии при грыжах дисков поясничного отдела позвоночника // Вестник Российского государственного медицинского университета. 2011. № 1. С. 36–40.

[37] Borisov IM, Shapovalova TG, Krainyukov PE. Indirect lymphotropic therapy at pneumonia. Yakut Medical Journal. 2011;(3):34–36. (In Russ).

[38] Борисов И.М., Шаповалова Т.Г., Крайнюков П.Е. Непрямая лимфотропная терапия при пневмонии // Якутский медицинский журнал. 2011. № 3. С. 34–36.

[39] Krotov SY, Krotov YA, Putalova IN. Regional lymphotropic therapy for acute otitis media using low-frequency ultrasound. Russian Otorhinolaryngology. 2013;64(3):89–93. (In Russ).

[40] Кротов С.Ю., Кротов Ю.А., Путалова И.Н. Регионарная лимфотропная терапия острого среднего отита с использованием низкочастотного ультразвука // Российская оториноларингология. 2013. № 3. С. 89–93.

[41] Bratko VI, Smagin AA, Khabarov DV, Demura AY. Use of lymphotropic technologies for the correction of the inflammatory process in diabetic retinopathy. Mezhdunarodnyi zhurnal ehksperimental’nogo obrazovaniya. 2013;(10-2):246–249. (In Russ).

[42] Братко В.И., Смагин А.А., Хабаров Д.В., Демура А.Ю. Применение лимфотропных технологий для коррекции воспалительного процесса при диабетической ретинопатии // Международный журнал экспериментального образования. 2013. № 10-2. С. 246–249.

[43] Volchegorskij IA, Dolgushin II, Kolesnikov OL, i dr. Jeksperimental’noe modelirovanie i laboratornaja ocenka adaptivnyh reakcij organizma. Cheljabinsk: Izd-vo Cheljabinskogo gosudarstvennogo pedagogicheskogo universiteta; 2000. 167 p. (In Russ).

[44] Волчегорский И.А., Долгушин И.И., Колесников О.Л., и др. Экспериментальное моделирование и лабораторная оценка адаптивных реакций организма. Челябинск : Изд-во Челябинского государственного педагогического университета, 2000. 167 с.

[45] Thomas JR, Wallace MS, Yocum RC, et al. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J Pain Symptom Manage. 2009; 38(5):663–678. doi.org/10.1016/j.jpainsymman.2009.03.009

[46] Thomas J.R., Wallace M.S., Yocum R.C., et al. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness // J Pain Symptom Manage. 2009. Vol. 38, N 5. P. 663–678. doi: 10.1016/j.jpainsymman.2009.03.009

[47] https://grls.rosminzdrav.ru/ [Internet]. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata LongidazA® (Longidaza®) [cited: Feb 01, 2023]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=24753d71-5447-43ae-a8b7-46ae45216a0a (In Russ).

[48] https://grls.rosminzdrav.ru/ [интернет]. Инструкция по медицинскому применению лекарственного препарата Лонгидаза® (Longidaza®) [дата обращения: 01.02.2023]. Доступ по ссылке: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=24753d71-5447-43ae-a8b7-46ae45216a0a

[49] Kukushkin GV, Zhuravleva MV, Sviridkina LP, Yurov DE. Hyaluronidase: an experimental confirmation of the properties of the endolymphatic conductor. Rossiiskii meditsinskii zhurnal (Medical Journal of the Russian Federation, Russian Journal). 2019;25(1): 40–43. (In Russ). doi: 10.18821/0869-2106-2019-25-1-40-43

[50] Кукушкин Г.В., Журавлева М.В., Свиридкина Л.П., Юров Д.Е. Гиалуронидаза: экспериментальное подтверждение свойств эндолимфатического проводника // Российский медицинский журнал. 2019. Т. 25, № 1. С. 40–43. doi: 10.18821/0869-2106-2019-25-1-40-43

[51] Zhuravleva MV, Kukushkin GV, Sviridkina LP, et al. Experimental study of the pharmacokinetics of cefotaxime with joint administration of drugs with hyaluronidase activity. Antibiotics and Chemotherapy. 2019;64(5-6):9–12. (In Russ). doi: 10.24411/0235-2990-2019-10024

[52] Журавлева М.В., Кукушкин Г.В., Свиридкина Л.П., и др. Экспериментальное изучение фармакокинетики цефотаксима при совместном введении с препаратами, обладающими гиалуронидазной активностью // Антибиотики и химиотерапия. 2019. Т. 64, № 5-6. С. 9–12. doi: 10.24411/0235-2990-2019-100024

RIGHTS & PERMISSIONS

Eco-Vector